Controlled release delivery system for nasal application of neurotransmitters
View Patent ↗This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct or partly direct transport from nose to the brain.
1. A method of providing dopaminergic activity to brain tissue of a subject in need thereof, comprising administering a dopamine gel formulation to the nasal mucosa of the subject, wherein the dopamine gel formulation comprises:
(a) dopamine in an amount of from about 0.01% to about 6% by weight of the dopamine gel formulation;
(b) castor oil in an amount of from 75% to about 95% by weight of the dopamine gel formulation;
(c) oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides in an amount of from about 0.5% to about 20% by weight of the dopamine gel formulation; and
(d) colloidal silicon dioxide in an amount of from about 0.5% to about 10% by weight of the dopamine gel formulation.
2. The method according to claim 1 , wherein the amount of said dopamine administered is about 0.001 milligram to about 200 milligrams per kilogram of body weight.
3. A method of providing controlled release and delivery of dopamine to cerebrospinal fluid (CSF) and/or brain tissue of a subject in need thereof, comprising administering a dopamine gel formulation to the nasal mucosa of the subject, wherein the dopamine gel formulation comprises:
(a) dopamine in an amount of about 0.01% to about 6% by weight of the dopamine gel formulation;
(b) castor oil in an amount of from 75% to about 95% by weight of the dopamine gel formulation;
(c) oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides in an amount of from about 0.5% to about 20% by weight of the dopamine gel formulation; and
(d) colloidal silicon dioxide in an amount of from about 0.5% to about 10% by weight of the dopamine gel formulation.
4. The method of claim 3 , wherein the amount of dopamine administered is from about 0.001 milligram to about 200 milligrams per kilogram of body weight per day.
5. The method of claim 3 , wherein said dopamine is about 2% by weight of the formulation.
6. The method of claim 1 , wherein said oleoyl macrogolglyceride or a mixture of oleoyl macrogolglycerides is about 4% by weight of the dopamine gel formulation.
7. The method of claim 1 , wherein the colloidal silicon dioxide is about 4% by weight of the dopamine gel formulation.
8. The method of claim 3 , wherein said dopamine in the gel formulation is in microspheres.
9. The method of claim 3 , wherein said dopamine in the gel formulation is in liposomes.
10. The method of claim 1 , wherein the subject has a disease associated with dopamine deficiency in the brain.
11. The method of claim 10 , wherein the disease is selected from the group consisting of depression, Parkinson's disease, attention deficit hyperactivity disorder (ADHA), Alzheimer's disease, a psychiatric disorder, loss of libido, drug addiction, alcohol addiction and aggression.
12. The method of claim 1 , wherein the method provides an anti-depressive-like effect.
13. The method of claim 1 , wherein the subject is a male.
14. The method of claim 3 , wherein the method provides controlled release and delivery of dopamine into the neostriatum and ventral striatum (nucleus accumbens) of the brain.
15. The method of claim 3 , wherein the dopamine gel formulation comprises about 4% dopamine based on the weight of the gel formulation.
16. The method of claim 3 , wherein the method results in increased dopaminergic activity in the nucleus accumbens, and wherein administering the dopamine gel formulation does not increase physiological levels of 3,4-dihydroxyphenyl acetic acid in the nucleus accumbens within two hours after administration.
17. The method of claim 3 , wherein the method results in increased dopaminergic activity in the neostriatum, and wherein administering the dopamine gel formulation does not increase physiological levels of 3,4-dihydroxyphenyl acetic acid in the neostriatum within two hours after administration.